尤其是在cMET高表达人群,LUMINOSITY试验表现出更显著的优势,ABBV-400在≥25%细胞ICH3+患者和≥50%细胞ICH3+患者中均表现出显著优于2L+ NSQ EGFR WT NSCLC患者(48 pts)的疗效(ORR分别为60.0%和77.8%),ABBV-399在cMET高表达(78 pts)和cMET中表达(83 pt...
中国上市:近日,国家药品监督管理局药品审评中心(CDE)正式将艾伯维临床研发阶段的输注用无菌冻干粉Telisotuzumab Vedotin(Teliso-V)纳入突破性治疗药物品种名单,拟用于治疗在铂类药物治疗期间或治疗后发生疾病进展的c-Met 蛋白高表达(OE)晚期/转移性表皮生长因子受体(EGFR)野生型(WT)非鳞状(NSq)非小细胞肺癌(NSCLC)...
;12.仅限扩展第 2 部分: -组织学诊断为恶性实体瘤(世界卫生组织 [WHO] 标准)。 -根据 RECIST 1.1 版,存在可测量的疾病。 -受试者患有晚期实体瘤,包括(但不限于)非小细胞肺癌(NSCLC)、头颈部鳞状细胞癌(HNSCC)、胃食管连接部腺癌(GEA)、结肠直肠癌 (CRC)和肾细胞癌(RCC),其在标...
1257MO ABBV-400, a c-Met protein-targeting antibody-drug conjugate (ADC), in patients (Pts) with advanced EGFR wildtype (WT) non-squamous (NSQ) non-small cell lung cancer (NSCLC): Results from a phase I studydoi:10.1016/j.annonc.2024.08.1314M. De Miguel...
Park and Kasi Expand on Perioperative Immunotherapy Updates in CRC March 11th 2025 First-Line T-DXd ± Pertuzumab Yields Durable Responses in HER2+ Metastatic Breast Cancer March 11th 2025 Dato-DXd Plus Durvalumab ± Carbopl...
Preclinically ABBV-400 exhibits favorable pharmacokinetics, anti-proliferative activity in vitro, and compelling efficacy in NSCLC, gastroesophageal, and CRC xenograft models. Furthermore, ABBV-400 is well tolerated by cynomolgus monkeys with bone marrow and gastrointestinal tract toxicities common to other...